N@N

GENZ, HAR, ACOR, ELP, CHU, AHT. Abnormal Price Friction In Morning Trading Session Today

^{Published on 2009-06-16 08:01:02, Last Modified on 2010-12-22 14:13:43 - WOPRAI}
 

June 16, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for June 16, 2009. Since late October market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This fair market making requirement is designed to prevent market makers from manipulating stock prices. Here is a list of the companies with Abnormal Price Friction (unfair market) in their stock prices in today�s trading session. This means that there was more buying than selling in the stocks and their stock prices dropped. Genzyme (NASDAQ: GENZ), Harman International (NYSE: HAR), Acorda Therapeutics (NASDAQ: ACOR), Companhia Paranaense de Energia (NYSE: ELP), China Unicom Hong Kong (NYSE: CHU) and Ashford Hospitality Trust (NYSE: AHT). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

Symbol Change % BuyVol Buy% SellVol Sell% NetVol Friction

GENZ -$2.95 -5.30% 2,916,616 50.16% 2,829,711 48.67% 86,905 abnormal

HAR -$2.24 -9.61% 239,114 35.36% 204,249 30.20% 34,865 abnormal

ACOR -$1.23 -4.64% 47,739 52.13% 43,830 47.87% 3,909 abnormal

ELP -$0.80 -5.25% 69,052 43.92% 62,883 39.99% 6,169 abnormal

CHU -$0.65 -4.49% 449,322 50.15% 312,895 34.92% 136,427 abnormal

AHT -$0.59 -15.32% 210,742 52.68% 129,931 32.48% 80,811 abnormal

Click here to view chart:

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above had more buying than selling on Tuesday, June 16th, 2009 and their stock prices dropped. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows GENZ with 86,905 greater shares of buying than selling (NetVol) and the stock price was down -$2.95. This means the Market Makers were trading the stock in a way inconsistent with normal supply and demand (Economics 101); more buying than selling should cause prices to rise.

Genzyme Corporation (NASDAQ: GENZ) operates as a biotechnology company worldwide. The company�s Genetic Diseases segment manufactures and distributes therapeutic products, including Cerezyme as an enzyme replacement therapy for the treatment of Type 1 and Type 3 Gaucher diseases; Fabrazyme, a recombinant form of the human enzyme alpha- galactosidase for the treatment of Fabry disease; Myozyme as a therapy for Pompe disease; and Aldurazyme for the treatment of Mucopolysaccharidosis I. This segment markets and sells its products directly to physicians, hospitals, treatment centers, pharmacies, and government agencies through distributors. Its Cardiometabolic and Renal segment develops, manufactures, and distributes products consisting of Renagel and Renvela for the control of serum phosphorus in patients with chronic kidney disease on dialysis; Hectorol, a line of vitamin D2 pro-hormone products for the treatment of secondary hyperparathyroidism; and Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with well-differentiated thyroid cancer. This segment sells its products to retail pharmacies, hospitals, and other providers of medication to patients. The company�s Biosurgery segment provides biotherapeutics and biomaterial-based products, which comprise Synvisc, a biomaterial-based product that is used to treat the pain associated with osteoarthritis of the knee; and Sepra family of products to prevent adhesions following various surgical procedures in the abdomen and pelvis. Its Hematologic Oncology segment develops products for the treatment of cancer, which include Campath for the treatment of B-cell chronic lymphocytic leukemia; Clolar for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia; and Mozobil for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The company was founded in 1981 and is based in Cambridge, Massachusetts.

Harman International Industries, Incorporated (NYSE: HAR) and its subsidiaries engage in the design, manufacture, and marketing of audio products and electronic systems worldwide. The company operates in three segments: Automotive, Consumer, and Professional. The Automotive segment designs, manufactures, and markets audio, electronic, and infotainment systems for vehicle applications primarily to be installed as original equipment by automotive manufacturers. This segment offers its products under JBL, Infinity, Harman/Kardon, Becker, Logic 7, and Mark Levinson brand names. The Consumer segment engages in the design, manufacture, and marketing of audio and electronic systems for home, mobile, and multimedia applications. This segment offers its products under JBL, Infinity, Harman/Kardon, Lexicon, Mark Levinson, Revel, and AKG brand names through audio/video specialty and retail chain stores. The Professional segment designs, manufactures, and markets loudspeakers and electronic systems used by audio professionals in concert halls, stadiums, airports, and other buildings, as well as for recording, broadcast, cinema, and music reproduction applications. It also provides products to the sound reinforcement, music instrument support, and broadcast and recording segments of the professional audio market. In addition, Professional segment offers systems solutions for professional installations and users. This segment markets its products under the JBL Professional, AKG, Crown, Soundcraft, Lexicon, DigiTech, dbx, and Studer brand names. The company was founded in 1980 and is headquartered in Stamford, Connecticut.

Acorda Therapeutics, Inc. (NASDAQ: ACOR), a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company�s lead product candidate is Fampridine-SR, which completed two positive Phase III clinical trials for the improvement of walking ability in patients with MS. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.

Companhia Paranaense de Energia (NYSE: ELP) COPEL, through its subsidiaries, engages in the generation, transmission, and distribution of electricity in the state of Parana, Brazil. As of December 31, 2007, the company operated 17 hydroelectric plants and 1 thermoelectric plant, with a total installed capacity of 4,549.6 megawatts. It also owned and operated 1,830 kilometers of transmission lines and 177,046 kilometers of distribution lines. Companhia Paranaense de Energia serves industrial, residential, commercial, and rural and other customers. In addition, it offers telecommunications and other services; water and sewage; natural gas distribution; and consulting services businesses. The company was founded in 1954 and is based in Curitiba, Brazil.

China Unicom (Hong Kong) Limited (NYSE: CHU) provides telecommunications services in the People's Republic of China. The company offers GSM telephone and related services, fixed-line voice and value-added services, broadband and other Internet-related services, information communications technology services, business and data communications services, and advertising and media services, as well as long distance services. As of December 31, 2008, it served approximately 133.365 million GSM subscribers in 31 provinces, municipalities, and autonomous regions in the Mainland China. China Unicom (Hong Kong) Limited has a strategic cooperation agreement with Baidu Inc. to jointly develop wireless search services. The company was formerly known as China Unicom Limited and changed its name to China Unicom (Hong Kong) Limited in October 2008. China Unicom (Hong Kong) Limited was founded in 2000 and is based in Central, Hong Kong. China Unicom (Hong Kong) Limited operates as a subsidiary of China Unicom (BVI) Limited.

Ashford Hospitality Trust, Inc. (NYSE: AHT), a real estate investment trust (REIT), invests in the hospitality industry primarily in the United States. The company invests in various segments and at various levels of the capital structure, including direct hotel investments, first mortgages, mezzanine loans, construction loans, and sale-leaseback transactions. It primarily concentrates among Marriott, Hilton, Hyatt, and Starwood brands. As of December 31, 2006, the company owned 81 hotel properties in 26 states with 15,492 rooms and an office building. Its portfolio also includes 24 full-service, upper-upscale hotels containing 8,069 rooms, as well as 27 premium select-service hotels consisting of 5,571 rooms in 31 markets throughout 18 states, the District of Columbia, and Canada. Ashford Hospitality Trust has elected to be taxed as REIT for federal income tax purposes and would not be subject to income tax to the extent that it distributes at least 90% of its REIT taxable income to its stockholders. Ashford Hospitality Trust was founded in 1968 and is based in Dallas, Texas.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,600,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. None of the companies in this report have paid to be included in this report. From time to time we will mention a company that may have previously paid $995 per month for market data purchased from BUYINS.NET. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET, FRICTION FACTOR and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net